Teratogenic effect of hydroxyethylrutoside, a flavonoid derivate drug-a population-based case-control study

Éva Pósfai, F. Bánhidy, E. Czeizel

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Objective: Hydroxyethylrutoside (HER), a flavonoid derivate drug, used frequently in pregnant women for the treatment of vascular diseases. The aim of this case-control study was to evaluate the teratogenic potential of oral HER treatment in the population-based Hungarian Case-Control Surveillance System of Congenital Abnormalities. Methods: Comparative analysis of exposure (HER treatment) during pregnancy in the mothers of cases with congenital abnormalities and matched control newborns without any defect in the population-based Hungarian Case-Control Surveillance System of Congenital Abnormalities. Results: Of the 22843 cases with congenital abnormalities, 567 (2.5%) had mothers with HER treatment while of 38151 matched controls, 1143 (3.0%) were born to mothers with HER treatment (OR with 95% CI: 0.8, 0.7-0.9). However, an association of HER treatment during the second and/or third month of pregnancy was found with the higher risk of unilateral ocular coloboma (OR with 95% CI: 5.4, 2.2-12.9) and a new congenital abnormality syndrome including anotia/microtia, poly/syndactyly and caudal (genital and anal) defects (OR with 95% CI: 3.0, 1.3-27.4). Conclusions: Oral HER treatment during early pregnancy associates with a higher risk for ocular coloboma and for a newly delineated congenital abnormality syndrome.

Original languageEnglish
Pages (from-to)1093-1098
Number of pages6
JournalJournal of Maternal-Fetal and Neonatal Medicine
Volume27
Issue number11
DOIs
Publication statusPublished - 2014

Fingerprint

Hydroxyethylrutoside
Flavonoids
Case-Control Studies
Pharmaceutical Preparations
Population
Coloboma
Mothers
Pregnancy
Therapeutics
Syndactyly
Vascular Diseases
Pregnant Women
Newborn Infant

Keywords

  • Congenital abnormalities
  • Hydroxyethylrutoside
  • New congenital abnormality syndrome
  • Ocular coloboma
  • Population-based case-control study
  • Pregnancy

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Obstetrics and Gynaecology
  • Medicine(all)

Cite this

@article{2d81f322468940d093f123cdaaa08429,
title = "Teratogenic effect of hydroxyethylrutoside, a flavonoid derivate drug-a population-based case-control study",
abstract = "Objective: Hydroxyethylrutoside (HER), a flavonoid derivate drug, used frequently in pregnant women for the treatment of vascular diseases. The aim of this case-control study was to evaluate the teratogenic potential of oral HER treatment in the population-based Hungarian Case-Control Surveillance System of Congenital Abnormalities. Methods: Comparative analysis of exposure (HER treatment) during pregnancy in the mothers of cases with congenital abnormalities and matched control newborns without any defect in the population-based Hungarian Case-Control Surveillance System of Congenital Abnormalities. Results: Of the 22843 cases with congenital abnormalities, 567 (2.5{\%}) had mothers with HER treatment while of 38151 matched controls, 1143 (3.0{\%}) were born to mothers with HER treatment (OR with 95{\%} CI: 0.8, 0.7-0.9). However, an association of HER treatment during the second and/or third month of pregnancy was found with the higher risk of unilateral ocular coloboma (OR with 95{\%} CI: 5.4, 2.2-12.9) and a new congenital abnormality syndrome including anotia/microtia, poly/syndactyly and caudal (genital and anal) defects (OR with 95{\%} CI: 3.0, 1.3-27.4). Conclusions: Oral HER treatment during early pregnancy associates with a higher risk for ocular coloboma and for a newly delineated congenital abnormality syndrome.",
keywords = "Congenital abnormalities, Hydroxyethylrutoside, New congenital abnormality syndrome, Ocular coloboma, Population-based case-control study, Pregnancy",
author = "{\'E}va P{\'o}sfai and F. B{\'a}nhidy and E. Czeizel",
year = "2014",
doi = "10.3109/14767058.2013.850485",
language = "English",
volume = "27",
pages = "1093--1098",
journal = "Journal of Maternal-Fetal and Neonatal Medicine",
issn = "1476-7058",
publisher = "Informa Healthcare",
number = "11",

}

TY - JOUR

T1 - Teratogenic effect of hydroxyethylrutoside, a flavonoid derivate drug-a population-based case-control study

AU - Pósfai, Éva

AU - Bánhidy, F.

AU - Czeizel, E.

PY - 2014

Y1 - 2014

N2 - Objective: Hydroxyethylrutoside (HER), a flavonoid derivate drug, used frequently in pregnant women for the treatment of vascular diseases. The aim of this case-control study was to evaluate the teratogenic potential of oral HER treatment in the population-based Hungarian Case-Control Surveillance System of Congenital Abnormalities. Methods: Comparative analysis of exposure (HER treatment) during pregnancy in the mothers of cases with congenital abnormalities and matched control newborns without any defect in the population-based Hungarian Case-Control Surveillance System of Congenital Abnormalities. Results: Of the 22843 cases with congenital abnormalities, 567 (2.5%) had mothers with HER treatment while of 38151 matched controls, 1143 (3.0%) were born to mothers with HER treatment (OR with 95% CI: 0.8, 0.7-0.9). However, an association of HER treatment during the second and/or third month of pregnancy was found with the higher risk of unilateral ocular coloboma (OR with 95% CI: 5.4, 2.2-12.9) and a new congenital abnormality syndrome including anotia/microtia, poly/syndactyly and caudal (genital and anal) defects (OR with 95% CI: 3.0, 1.3-27.4). Conclusions: Oral HER treatment during early pregnancy associates with a higher risk for ocular coloboma and for a newly delineated congenital abnormality syndrome.

AB - Objective: Hydroxyethylrutoside (HER), a flavonoid derivate drug, used frequently in pregnant women for the treatment of vascular diseases. The aim of this case-control study was to evaluate the teratogenic potential of oral HER treatment in the population-based Hungarian Case-Control Surveillance System of Congenital Abnormalities. Methods: Comparative analysis of exposure (HER treatment) during pregnancy in the mothers of cases with congenital abnormalities and matched control newborns without any defect in the population-based Hungarian Case-Control Surveillance System of Congenital Abnormalities. Results: Of the 22843 cases with congenital abnormalities, 567 (2.5%) had mothers with HER treatment while of 38151 matched controls, 1143 (3.0%) were born to mothers with HER treatment (OR with 95% CI: 0.8, 0.7-0.9). However, an association of HER treatment during the second and/or third month of pregnancy was found with the higher risk of unilateral ocular coloboma (OR with 95% CI: 5.4, 2.2-12.9) and a new congenital abnormality syndrome including anotia/microtia, poly/syndactyly and caudal (genital and anal) defects (OR with 95% CI: 3.0, 1.3-27.4). Conclusions: Oral HER treatment during early pregnancy associates with a higher risk for ocular coloboma and for a newly delineated congenital abnormality syndrome.

KW - Congenital abnormalities

KW - Hydroxyethylrutoside

KW - New congenital abnormality syndrome

KW - Ocular coloboma

KW - Population-based case-control study

KW - Pregnancy

UR - http://www.scopus.com/inward/record.url?scp=84902951498&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902951498&partnerID=8YFLogxK

U2 - 10.3109/14767058.2013.850485

DO - 10.3109/14767058.2013.850485

M3 - Article

C2 - 24087950

AN - SCOPUS:84902951498

VL - 27

SP - 1093

EP - 1098

JO - Journal of Maternal-Fetal and Neonatal Medicine

JF - Journal of Maternal-Fetal and Neonatal Medicine

SN - 1476-7058

IS - 11

ER -